Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT EV-to-OCF is 17.58 as of Aug. 02, 2026, which is 145% above its 10-year median of 7.19. The stock has 8 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Vitura Health ranks worse than 65.28% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vitura Health's Enterprise Value is A$26.0 Mil.
Vitura Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.5 Mil. Therefore, Vitura Health's EV-to-OCF for today is 17.58.
The historical rank and industry rank for Vitura Health's EV-to-OCF or its related term are showing as below:
ASX:VIT'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.7 Med: 7.19 Max: 31.69
Current: 17.58
During the past 7 years, the highest EV-to-OCF of Vitura Health was 31.69. The lowest was -8.70. And the median was 7.19.
ASX:VIT's EV-to-OCF is ranked worse than 65.28% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.765
vs ASX:VIT: 17.58
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vitura Health's PE Ratio (TTM) for today is calculated as:
Vitura Health's share price for today is A$0.026.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitura Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vitura Health EV-to-OCF Related Terms
Vitura Health EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vitura Health's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vitura Health's EV-to-OCF falls into.
Vitura Health's current Enterprise Value is A$26.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vitura Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a EV-to-OCF of 17.58 as of Aug. 02, 2026. This is 145% above median its historical median of 7.19. According to the industry distribution chart, Vitura Health ranks #658 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 65.3%.
Is Vitura Health's EV-to-OCF too high?
Vitura Health's current EV-to-OCF of 17.58 is 145% above median its 10-year median of 7.19. The Drug Manufacturers industry median EV-to-OCF is 10.77. Vitura Health's value of 17.58 is 63.3% above this industry median. Based on the distribution chart, Vitura Health ranks #658 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Vitura Health's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #658 out of 1008 companies for EV-to-OCF. This places Vitura Health in the lower half of its industry. The industry median EV-to-OCF is 10.77. Vitura Health's value of 17.58 is 63.3% above this benchmark. While the company's 10-year median is 7.19 vs. the industry median of 10.77, Vitura Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.77, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current EV-to-OCF of 17.58 is 63.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current EV-to-OCF is 17.58, which is 145% above median its own 10-year median of 7.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 74% below its estimated fair value. The current EV-to-OCF is 17.58, which is 145% above median its 10-year median of 7.19 and 63.3% above the Drug Manufacturers industry median of 10.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current EV-to-OCF is 17.58 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
